Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treatment effects on neurometabolite levels in schizophrenia: A systematic review and meta-analysis of proton magnetic resonance spectroscopy studies
Manabu Kubota, Sho Moriguchi, Keisuke Takahata, et al.
Schizophrenia Research (2020) Vol. 222, pp. 122-132
Closed Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of 1H-magnetic resonance spectroscopy studies
Tomomi Nakahara, Sakiko Tsugawa, Yoshihiro Noda, et al.
Molecular Psychiatry (2021) Vol. 27, Iss. 1, pp. 744-757
Closed Access | Times Cited: 105
Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level
Kate Merritt, Philip McGuire, Alice Egerton, et al.
JAMA Psychiatry (2021) Vol. 78, Iss. 6, pp. 667-667
Open Access | Times Cited: 97
Glutamatergic dysfunction in Schizophrenia
Andreas O. Kruse, Juan Bustillo
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 64
A meta-analysis of ultra-high field glutamate, glutamine, GABA and glutathione 1HMRS in psychosis: Implications for studies of psychosis risk
Valerie J. Sydnor, David R. Roalf
Schizophrenia Research (2020) Vol. 226, pp. 61-69
Open Access | Times Cited: 56
Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia
Grant McQueen, Kyra-Verena Sendt, Amy Gillespie, et al.
Schizophrenia Bulletin (2020) Vol. 47, Iss. 3, pp. 662-671
Open Access | Times Cited: 56
Medial Prefrontal Cortex Glutamate Is Reduced in Schizophrenia and Moderated by Measurement Quality: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies
Jason Smucny, Cameron S. Carter, Richard J. Maddock
Biological Psychiatry (2021) Vol. 90, Iss. 9, pp. 643-651
Open Access | Times Cited: 34
Neurobiology and Applications of Inositol in Psychiatry: A Narrative Review
Carmen Concerto, Cecilia Chiarenza, Antonio Di Francesco, et al.
Current Issues in Molecular Biology (2023) Vol. 45, Iss. 2, pp. 1762-1778
Open Access | Times Cited: 15
Disrupted subcortical functional connectome gradient in drug-naïve first-episode schizophrenia and the normalization effects after antipsychotic treatment
Chengmin Yang, Wenjing Zhang, Jiajun Liu, et al.
Neuropsychopharmacology (2022) Vol. 48, Iss. 5, pp. 789-796
Open Access | Times Cited: 20
The impact of cannabidiol treatment on resting state functional connectivity, prefrontal metabolite levels and reward processing in recent-onset patients with a psychotic disorder
Ruben van Boxel, Shiral S. Gangadin, Hella Janssen, et al.
Journal of Psychiatric Research (2023) Vol. 163, pp. 93-101
Open Access | Times Cited: 11
Association between white blood cell counts and the efficacy on cognitive function after rTMS intervention in schizophrenia
Suzhen Ye, Bailing Wang, Heling Sui, et al.
Schizophrenia (2025) Vol. 11, Iss. 1
Open Access
The Relationship of glutamate signaling to cannabis use and schizophrenia
Margaret Niznikiewicz, Alexander P. Lin, Lynn E. DeLisi
Current Opinion in Psychiatry (2025)
Closed Access
Glutamate in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia: A Meta-analysis of 1H-Magnetic Resonance Spectroscopy Studies
Jakob Kaminski, Lea Mascarell-Maricic, Yu Fukuda, et al.
Biological Psychiatry (2020) Vol. 89, Iss. 3, pp. 270-277
Closed Access | Times Cited: 28
Anterior cingulate glutamate metabolites as a predictor of antipsychotic response in first episode psychosis: data from the STRATA collaboration
Alice Egerton, Kira Griffiths, Cecila Casetta, et al.
Neuropsychopharmacology (2022) Vol. 48, Iss. 3, pp. 567-575
Open Access | Times Cited: 17
Progressive Changes in Glutamate Concentration in Early Stages of Schizophrenia: A Longitudinal 7-Tesla MRS Study
Peter Jeon, Roberto Limongi, Sabrina D. Ford, et al.
Schizophrenia Bulletin Open (2020) Vol. 2, Iss. 1
Open Access | Times Cited: 27
Brain glutamate concentration in men with early psychosis: a magnetic resonance spectroscopy case–control study at 7 T
Beata R. Godlewska, Amedeo Minichino, Uzay E. Emir, et al.
Translational Psychiatry (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 23
Metabolite differences in the medial prefrontal cortex in schizophrenia patients with and without persistent auditory verbal hallucinations: a 1H MRS study
Qianjin Wang, Honghong Ren, Chunwang Li, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 15
Meta-analytic evidence of elevated choline, reduced N-acetylaspartate, and normal creatine in schizophrenia and their moderation by measurement quality, echo time, and medication status
Yvonne S. Yang, Jason Smucny, Huailin Zhang, et al.
NeuroImage Clinical (2023) Vol. 39, pp. 103461-103461
Open Access | Times Cited: 8
Glutamatergic basis of antipsychotic response in first-episode psychosis: a dual voxel study of the anterior cingulate cortex
Lejia Fan, Liangbing Liang, Yujue Wang, et al.
Neuropsychopharmacology (2023) Vol. 49, Iss. 5, pp. 845-853
Open Access | Times Cited: 8
Systematic Review of the Neural Effect of Electroconvulsive Therapy in Patients with Schizophrenia: Hippocampus and Insula as the Key Regions of Modulation
Sun-Young Moon, Minah Kim, Silvia Kyungjin Lho, et al.
Psychiatry Investigation (2021) Vol. 18, Iss. 6, pp. 486-499
Open Access | Times Cited: 18
Differential effects of cannabis constituents on schizophrenia-related psychosis: a rationale for incorporating cannabidiol into a schizophrenia therapeutic regimen
Kennadi Johnson, Abby J. Weldon, Melissa A. Burmeister
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 2
The trajectory of putative astroglial dysfunction in first episode schizophrenia: a longitudinal 7-Tesla MRS study
Peter Jeon, Michael Mackinley, Jean Théberge, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 15
The cortical silent period in schizophrenia: A systematic review and meta-analysis focusing on disease stage and antipsychotic medication
Atsuhiro Miyazawa, Nobuhisa Kanahara, Yuki Shiko, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 4, pp. 479-488
Closed Access | Times Cited: 8
Improved patient identification by incorporating symptom severity in deep learning using neuroanatomic images in first episode schizophrenia
Wenjing Zhang, Lituan Wang, Xu‐Sha Wu, et al.
Neuropsychopharmacology (2024)
Closed Access | Times Cited: 1
Increased Glutamate Plus Glutamine in the Right Middle Cingulate in Early Schizophrenia but Not in Bipolar Psychosis: A Whole Brain 1H-MRS Study
Juan Bustillo, Elizabeth Grace Mayer, Joel Upston, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 9
The effect of antipsychotics on glutamate levels in the anterior cingulate cortex and clinical response: A 1H-MRS study in first-episode psychosis patients
Uzma Zahid, Robert A. McCutcheon, Faith Borgan, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top